glp1 tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Semaglutide & Tirzepatide Weight Loss

Craig Primack, Hims & Hers SVP of Weight Management, joins 'Closing Bell Overtime' to talk the company offering a GLP-1 drug through its platform.

We conducted a retrospective multicenter national study examining the risk of gastric and esophageal cancer in patients with type 2 diabetes who were receiving glucagon-like peptide receptor agonists

Donna H

Qui na jamais eu un patient diabtique de type 2, obse, mal contrl, sous antidiabtiques oraux et insuline, et prenant du poids avec lescalade thr...

vitamin D intake ~20% of recommendations Lean mass risk: protein + calcium insufficiency may contribute, alongside other drivers B-vitamins: thiamine and cobalamin deficits appear to increase over time Clinical takeaway (my approach): GLP-1s dont cause malnutrition in everyone but they can unmask risk in the wrong context (older adults, low-protein diets, restrictive eating patterns, prolonged nausea/vomiting, rapid weight loss, post-bariatric patients)

Consult Pharmacy Planet for personalized expert guidance and start your weight loss journey today.